Centrexion Therapeutics currently has several ongoing clinical trials for the development of its novel, non-opioid and non-addictive therapies for the treatment of chronic pain.

If you or someone you know is interested in participating in one of the Centrexion Therapeutics clinical trials, please talk to your doctor or visit clinicaltrials.gov for more information on our studies and inclusion criteria.


The VICTORY-1 Phase 3 double-blind, placebo-controlled trial of CNTX-4975 in patients with moderate-to-severe knee OA commenced in February 2018. The trial has completed enrollment and is no longer recruiting patients.


The VICTORY-2 study is a 52-week clinical trial of CNTX-4975 examining capsaicin and its potential to provide extended relief from osteoarthritis knee pain. The trial commenced in the second half of 2018.

303 Study

303 Study is an open-label trial treating patients with knee osteoarthritis will explore different ways to administer CNTX-4975 and may explore treatment of bilateral osteoarthritis of the knees as well. The trial commenced in the second half of 2019.